Search results
16 sty 2023 · SMARCB1 (INI-1)-deficient sinonasal carcinoma is a rare, poorly differentiated neoplasm with a poor prognosis. Though historically most were identified as sinonasal undifferentiated carcinoma, we now understand it to be a distinct entity.
5 lip 2022 · Simple Summary. SMARCB1 (INI-1)-deficient sinonasal carcinoma is a rare but locally aggressive malignancy which usually presents very late with invasion into the orbits and intracranium, and compression of adjacent cranial nerves and their branches at diagnosis, and has a poor survival outcome.
26 kwi 2020 · In this article, we present a case of INI-1 (SMARCB1)–deficient sinonasal carcinoma, provide an overview of recent advances in histological and molecular classification of sinonasal malignancies, and discuss challenges of caring for patients with these rare malignancies, as well as potential treatment implications.
5 lip 2022 · (4) Conclusions: SMARCB1-deficient sinonasal carcinoma is an extremely aggressive sinonasal malignancy with a dismal prognosis. Early diagnosis and a multimodality treatment strategy are essential for a better treatment and survival outcome.
1 kwi 2020 · In the case of SMARCB1-deficient sinonasal carcinoma (SDSC), there is a paucity of evidence to suggest the most appropriate and efficacious course of management. In this report, we present a case of SDSC and systematically review the literature.
21 maj 2022 · SMARCB1-deficient sinonasal carcinoma, also known as integrase interactor 1 (INI-1) deficient carcinoma and characterized by the loss of immunohistochemical staining of SMARCB1, is an emerging rare malignant cancer of the nasal cavity and paranasal sinuses that accounts for approximately 3–6% of cancer cases of the nasal cavity and paranasal ...
5 lip 2022 · (4) Conclusions: SMARCB1-deficient sinonasal carcinoma is an extremely aggressive sinonasal malignancy with a dismal prognosis. Early diagnosis and a multimodality treatment strategy are essential for a better treatment and survival outcome.
